Bacteriotherapy for NF2 and its broader implications
- by Dr. Gary Brenner, Massachusetts General Hospital
---
Dr. Gary Brenner is a clinician-investigator in Pain Medicine at Massachusetts General
Hospital with over 30 years of experience investigating the interaction between the
immune and nervous systems, and the role this plays in health and disease. More
recently, his primary research focus has been on the development of novel gene- and
cell-based treatment strategies, including immunotherapeutic, for schwannoma. His
laboratory is the first group to propose the use of attenuated live bacteria for the
treatment of a benign neoplasm (e.g., schwannoma), and has generated substantial
preclinical data supporting this therapeutic strategy. Dr. Brenner has also served as
Program Director of the Massachusetts General Pain Medicine Fellowship for over 20 years.
Негізгі бет Bacteriotherapy for NF2 and its broader implications
Пікірлер